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1Abstract
The question we posed at the beginning of this thesis was whether, in the
presence of a clinical superiority of one of two possible treatments, it was
possible to find an appropriate statistical methodology that would allow us
to reach this goal. We were thus led to explore many possibilities to carry out
this analysis and randomly assign patients to the two treatments, as required
by the particular nature of these experiments. Specifically, we made a close
examination of the methods of randomization, especially appreciating the
flexibility of the adaptive responses, and could see the strengths of urn mod-
els. We started with the study of the urn for excellence, Polya’s urn. Next,
we analyzed some extensions and generalizations, focusing especially on two
kinds of urns with random reinforcement. We exposed the results obtained
throughout simulations concerning the convergence of the proportion of the
best treatment, which came from the comparison of the models studied. In
the end, we showed how the urn model works in a real case, comparing two
treatments with continuous response in one ICU trial on Melatonin. We’ll
see how the properties demonstrated in theory are confirmed in practice.
The project ends by giving a hint of a new adaptive model that we have
started to idealize in collaboration with the team of Prof. Parmigiani and
Prof. Trippa of the ”Biostatistics and Computational Biology” Department,
Harvard T.H. Chan School of Public Health.
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Introduction
In the mankind history, human people has been a✏icted by disease and
has attempted to plan treatments to cure or improve the su↵ering of the
a✏icted. So, it is desirable knowing which treatments work, which do not,
and whether one treatment is better than another.
When a clinical researcher wants to evaluate the treatment e cacy or
the safety of one therapy that is under investigation, he runs a clinical trial.
There are many kinds of experiments, but in these years randomized con-
trolled clinical trials (RCT) have become established as the method which
investigators must use to assess new treatments. They are characterized by
two key features:
1. At the same time, the new treatment is given to a group of patients (the
the treated group) and the another treatment, often the one most widely
used, is given to another group of patients (the the control group).
2. Patients are allocated to one group or another by randomization. This
3
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mechanism can be thought of as deciding on the treatment to be given
by tossing a coin.
Usually, the standard tool for patients allocation is the equal randomiza-
tion that assures the balanced assignment. In this case the sample size is
fixed in advanced and chosen on the basis of statistical power.
However, a condition of initial balance is not always the optimal solution.
Indeed, there is an ethical concern to treat as many subjects as possible with
the best treatment. Indeed, when the treatment is clearly lower / higher than
the other one, it is not acceptable to allocate randomly to that treatment
in less than 50 percent of cases. Moreover, the responses to treatments can
di↵er greatly, in the sense that not all the patients will react in the same way
to the treatment.
The study of these issues has stimulated the birth in the 70’s of a new
allocation policy to the treatments: the Response Adaptive Randomization
(RAR). We dedicated the first chapter to them. First, we will focus on some
considerations about the randomization process and then we will explain
briefly the two main areas of study: the optimal and the sequential designs.
The second chapter is devoted to the presentation of a particular kind
of adaptive design, the urn models. This method was introducted by Polya
in 1923 to describe the spread of some diseases and very soon it became
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the prototype for many statistical models in the clinical setting. Thanks
to the luck of its application, the Polya urn has been subjected to many
generalizations. In the models that we will examine, we will see that the
drawing rule could be di↵erent. These rules will have the possibility to add
the balls to the urn in the various stages of the experiment and will also
define a specific law for certain balls to change the color. In addition, once
one ball is randomly drawn, it can be assumed that any other ball is equally
likely to draw. After giving a brief idea of reinforcement, we will present one
of the models most used in clinical urn until now, the Randomized Play the
Winner Rule.
In the third chapter, we focus on a specific urn model that included for the
first time a distribution on the reinforcement. This model, the Reinforced
Urn Model, was presented by Muliere et al. in 2006 and was born as an
evolution of the Randomized Play the Winner Rule. The new idea based on
this method is to vary the number of balls in the urn inserted according to the
responses of the patient, creating change proportion much faster than using
the constant reinforcement. We will presente the model, explaining in detail
the variables that comes into play. Then we will focus on the asymptotic
results and inference problems.
The fourth chapter is dedicated to a generalization of the RRU model
introduced by Ghiglietti and Paganoni in 2013. We analyzed the theory and
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the application of this evolution pattern, including some thresholds within
the proportion of one type of treatment varies. At the end of the chapter,
we will performe several simulations to compare di↵erent properties of the
two models with the random reinforcement. In particular, we focus on the
convergence of the proportion of the balls that represents the best treatment.
In the last chapther, we show some practical applications. We present
the application on the dataset of one study about the use of melatonin in
ICU patients. The dataset is from the study on the use of melatonin on ICU
patients conducted in the ”San Paolo Hospital - University Campus”, Milan,
by the Doctors Iapichino and Mistraletti. We have re-designed the study
and resorted a way of allocation using the RRU models. We performed some
simulations to see if the new model is able to achieve the two main objectives:
determine the best treatment and minimize (maximize) the patient’s number
with the worst (best) treatment.
Finally, we conclude giving a hint of a new adaptive model that we have
started to idealize in collaboration with the team of Prof. Parmigiani and
Prof. Trippa of the ”Biostatistics and Computational Biology” Department,
Harvard T.H. Chan School of Public Health.
In the appendix we have been inserted the R code for the di↵erent simu-
lations.
Chapter 1
Adaptive Clinical Trials
In the clinical trials the patients enter sequentially and then they are
randomly allocate to one or more treatments. Typically, this study is divided
in three parts: design, run, analysis. Now, we focus on the first aspect and
we attempt to change the randomization rule during the allocation process.
1.1 Randomization Process
The randomization has many properties and its huge use in the clinical
context is justified by the fact that it promotes the comparability among the
study groups and it provides a probabilistic basis for the inference.
On the other hand, the use of randomization in medicine has raised up
many ethical discussions. Many scientists agree upon the fact that it is
7
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ethical to use the randomization in a state of pure equilibrium, where the
patient has supply to their consent to be investigated and is fully informed
about the potential risks and benefits of treatments.
Moreover we need to consider the delicate balance between individual
and collective ethics. The first one regards as optimal the individual health,
the second one has as main goal the public health. Some researchers argue
that this balance occurs only in stage I and stage II studies. In general the
question is controversial, but nowadays the randomization was accepted as a
good standard.
The second importat issue when one researcher runs the clinical trial is
about the sample size. Large sample size gives more information and ensures
a good level of statistical power, but it requires also higher costs. So, in this
case, we have to respond to statistical and economic needs at the same time.
Let us consider a clinical trial with n patients and k possible treatments.
Definition 1.1. A random sequence is a matrix (Kxn)
T = (T1...Tn)
0
where Ti = ej j = 1, ..., K and i = 1, ..., n with ej the identity vector.
In general, we are interested in the properties of the random sequence
and, in particular, in the asympotic properties of the allocation proportion.
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Definition 1.2. Let be n patients and k treatments. The allocation propor-
tion will be
N(n)
n
where the matrix N(n) = (N1(n), ..., Nk(n)) e Nj(n) = ⌃ni=1Tij
And necessary it has to be
||N(n)|| =
KX
j=1
Nj(n) = n
where ||N(n)|| is the norm of N.
Now, let us consider a response variables matrix
X = (X1, ...,Xn)
with
Xi = (Xi1, ..., XiK)
where Xi is the observed responses sequence when the i-th patient is inde-
pendent assigned to the treatment. We will consider only the models for Xi
conditionally to Ti.
Let us indicate
=n =  {T1, ...,Tn}
the sigma - algebra generated by the first n treatment assigned;
Xn =  {X1, ...,Xn}
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the sigma - algebra generated by the first n responses;
Zn =  {Z1, ...,Zn}
the sigma - algebra generated by the first n covariates.
Definition 1.3. Let
Fn = =n ⌦ Xn ⌦ Zn+1
be one random procedure defined by
 n = E(Tn|Fn 1)
where  n is Fn measurable.
We indicate  n the conditional probability of the treatments (1, 2, ..., K)
for the n-th patient conditionally to the first (n  1) responses to the treat-
ments and covariates.
Following this idea, we detect five di↵erent kinds of randomization
Complete Randomization when
 n = E(Tn|Fn 1) = E(Tn)
Restricted Randomization when
 n = E(Tn|Fn 1) = E(Tn|=n 1)
Response Adaptive Randomization when
 n = E(Tn|Fn 1) = E(Tn|=n 1,Xn 1)
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Covariate Adaptive Randomization when
 n = E(Tn|Fn 1) = E(Tn|=n 1, Zn)
Adjusted-Covariate Response Adaptive Randomization when
 n = E(Tn|Fn 1) = E(Tn|=n 1,Xn 1, Zn).
1.2 Response Adaptive Randomization
In this work we focus on one of the randomization processes above pre-
sented, the Response Adaptive Randomization - RAR. This method uses the
information gathered during the trial to sequentially change the allocation
probability to one treatment.
The main reason for our choice is the ethical concern. Indeed, using this
method we try to simultaneously meet both an individual ethical component,
providing for the individual patient the best care possible, and a collective
ethical one, providing for the population su↵ering from a disease su cient
proof of a drug.
The RAR strength is the fact of being more flexible to the changes that
the researcher might meet during an experiment and to be able to absorb the
information even modifying the initial design for scientific needs. The reasons
that led us to study this strategy are di↵erent. First, the adaptive models
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exploit the information available at present and to the past, permitting the
reconstruction of a trend at each instant and, therefore, understanding the
evolution of the entire process. So, we will have a combination of past and
present data. We can work with continous and binary data. Our main
objectives are two: determine the best treatment and maximize the number
of patients in the experiment that receives the best treatment.
1.2.1 The Optimal Designs
The RAR is part of a particular kind of methodology: the Optimal De-
sign. The main purpose of these designs is to allocate the patients in a
optimal manner, in the sense that they meet certain properties. The princi-
pal idea is finding the experiment that minimize the loss of information. The
Optimal Designs contain a wide range of models. In the clinical context the
most commonly used are the D - Optimal ones, where D means the determi-
nant, as this method minimizes the determinant of the variance/covariance
matrix of the estimates of parameters. These strategies aim to maximize the
information matrix D = |X 0X|. The principal objectives of these designs
are obtaining precise estimates and assigning as many patients as possible to
the treatment that it is proving to do the best. The idea is to identify the
best treatment and increase the probability that this is could be chosen. The
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main components of the adaptive processes are: the identification of vari-
ables assessed at regular intervals during the treatment, the development of
alternative treatment options and modifications, the specification of the algo-
rithms that link the changes on the variables to the treatment modification,
the inclusion of the patients preferences.
The most important problem in this context is to achieve the optimal
allocation, as mentioned before. We start from a homogeneous population in
which the responses of patients assigned to the same treatment have the same
probability distribution. We suppose to have K treatments and the sample
size equal to n = (n1, ..., nK) such that n10 = n and the probability distri-
butions of the responses depend on the parameter ✓ 2 ⇥. Then, we have
a constrained optimization problem which include the sample size !(✓)n0,
where !(✓) = (!1(✓), ...,!K(✓)) are the possible positive weights probability
and ⌘(⌘, ✓) is the sample variance. So, our optimization problem is given by
min
n1,...,nK
!(✓)n0
sub ⌘(⌘, ✓) = C
where C is a constant value. Now, let us consider two competitive treatments,
called R and G, with binary responses. In particular, we know that pR is the
success probability to the treatment R and pG is the success probability to
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the treatment G, with qR = 1 pR and qG = 1 pG. We suppose to have one
fixed allocation nR for R and nG for G, with nR + nG = n and suppose that
we want to measure the di↵erence between the two treatments observing the
probability allocation of each of them. We run, then, a bilateral hypothesis
test where we compare the null hypothesis that the di↵erence between the
two treatments is statistically insignificant. That is
H0 : pR   pG = 0
versus
H1 : pR   pG 6= 0
The Wald test gives us
Z =
pˆR   pˆGq
pˆRqˆR
nR
+ pˆGqˆGnG
where pˆR, pˆG, qˆR, qˆG are the estimators. Our problem is about the sample
size needed to observe a significant di↵erence between the two treatments.
One solution can be fixing the test variance of the alternative hypothesis
and looking at the allocation n = (nR, nG) which minimizes the total sample
size. To simplify, we can set !1(✓) = !2(✓) = 1 and the unknown parameter
✓ = (pR, pG). The test for the variance becomes
⌘(⌘, ✓) =
pRqR
nR
+
pGqG
nG
CHAPTER 1. ADAPTIVE CLINICAL TRIALS 15
Knowing that ⌘(⌘, ✓) = C and substituting ⇢(✓) = nRn , we have
pRqR
⇢n
+
pGqG
(1  ⇢)n = C
and solving for n
n =
pRqR
⇢C
+
pGqG
(1  ⇢)C .
Now, minimizing respect to ⇢, we obtain
 pRqR
⇢2
+
pGqG
(1  ⇢)2 = 0
and then
⇢ =
p
pRqRp
pRqR +
p
pGqG
This is the Neyman allocation, as in the balanced design trial. In this case,
we can take advantage from the balanced trial in which the power of the test
is maximized. According to Rosenberger and Lachin (2005), the power of the
test is maximized when the equal allocation produces the response variables
to the treatment with same variance. When the variance of the response
variables is di↵erent, the power of the test should be maximized with the
allocation of patients to the treatment with higher variance. The weak point
of this procedure is when pR+pG > 1 the Neyman allocation directs a greater
number of patients to lower treatment. If we set !1(✓) = qR, !2(✓) = qG we
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have the RSIHR allocation (Rosenberger 2010)
⇢ =
p
pRp
pR +
p
pG
As we can see, the optimal allocation ⇢✓ depends on unknown parameters.
We can overcome the problem by replacing the data parameters, using the
methodology of the sequential design.
In general, when we run the response adaptive designs we have to con-
sider the correlation between the assigned treatments that can increase the
variability and adversely a↵ect the power of the test. Shortly, we have to
face the main problem of minimizing worst treatments and avoiding wasting
power. For Rosenberger and Hu (2003), this can happen imposing the nor-
mality assumption on the allocation proportions to the treatments. Infact,
in this case tha best allocation is the Neyman allocation.
1.2.2 The Sequential Designs
As we exposed before, the RAR procedures include a dynamic process
that assigns one patient to a given treatment following the probability that
is function of the respenses to the treatment and, consequently, will change
during the trial. The alternative way to the Optimal Designs to randomize
sequentially patients considering their responses, and then implement the
randomization of adaptive responses, it is a family of procedures based on
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sequential estimation.
The first procedure was introducted by Eisele (1994) and it is called the
doubly adaptive coin design. This design has inspired the research of many
authors and, thanks to the changes proposed by Hu and Zhang (2004), it gave
birth to one great part of the family of the procedures of adaptive responses.
This family includes all the procedures that have goals of allocations based on
unknown parameters of the model answers and that since the data increase,
sequentially updated estimates of these parameters.
Let us consider a generic clinical study with K possible treatments and
let us suppose that the patients are sequentially randomized and we can im-
mediately observe the responses to these treatments. When we randomized
the i-th patient and observed his response, the i + 1-th patient is allocated
to the k treatment with probability { i+1,k}, with k = 1, ..., K.
Let Ti = (Ti1, ..., TiK) be the vector that represents the outcome of the i-th
assignment, Xi the response of the i-th patient and Ni the allocation after
the i-th patient. Now, let us imagine that the proportion allocation of the
patients required, assigned to each treatment, is a function of some unknown
parameter of the answer X. A major purpose of this allocation scheme is
to get that the proportion allocation of the patients tents asymptotically to
a predetermined target allocation, considered optimal, the value of which is
a function of unknown parameters of the distribution of responses. Mathe-
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matically, we want to have
Nn
n
 !   = ⇢(⇥)
for n ! 1 where ⇢(z) = (⇢1(z), ..., ⇢k(z)) : Rd⇥K ! (0, 1)K is a vector of
a function such that ⇢(z)0 = 1, where ⇥ = (✓1, ..., ✓K) is a vector Rd⇥K and
✓k = (✓k1, ..., ✓kd) is a vector of unknown parameters of the distribution X1,k
with k = 1, ..., K. Imposing ⇥0 as the first estimate of the sample size ⇥.
When m patients are assigned and their responses are observed, we use the
sample mean to estimate ✓k, k = 1, ..., K
✓ˆik =
⌃ij=1Tj,kXj,k + ✓0,k
Ni,k + 1
and, consequently, ⇥ˆi,k = (✓ˆi,1, ..., ✓ˆi,K). The estimation of ⇥0 could be a
hypothesized value of ⇥ or an estimation of ⇥ obtained from the previous
trials.
Chapter 2
The Classical Urn Models
2.1 The idea of reinforcement
The urn models play an important role in studies adaptive response,
primarily because they ensure the randomization of the allocations. The first
use of the urn process in the clinical field is with the Polya Urn, exploited
in the past to study the contagious disease. Over the years, generalizations
and modifications of this particular method have a↵ected di↵erent aspects of
medical research, particularly for the clinical trials. The model introduced
by Polya consists of an urn with two colors.
Let us consider an urn initially containing r0   0 red balls and g0   0
green balls. At stage n = 1, 2, ... one ball is drawn from the urn and we
assign to the patient the treatment represented by that ball. In this way, we
19
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modify the urn composition following a particular rule.
The main assumption on the replacing process is that number of the balls
m > 0 added to each stage is constant. And this is the first idea of the
reinforcement. Following the definition
Definition 2.1. Muliere and Walker (2000).
Let (X1, X2, ...) be one sequence of random variables distributed as Bernoulli.
The observations are reinforced if
P (X2 = 1|X1 = 1)   P (X1 = 1)
and
P (X2 = 0|X1 = 0)   P (X1 = 0)
and, for every n   1 and x1, ..., xn 2 {0, 1}
P (Xn+2 = 1|X1 = x1, ...., Xn = xn, Xn+1 = 1)   P (Xn+1 = 1|X1 = x1, ...., Xn = xn)
This implies that
P (Xn+2 = 0|X1 = x1, ...., Xn = xn, Xn+1 = 0)   P (Xn+1 = 0|X1 = x1, ...., Xn = xn)
and, for every n   1 and x1, ..., xn 2 {0, 1}.
Then we have a random variables sequence {Xn} each of which will be
0 or 1 depending on red or white ball drawn at the stage n. Moreover, for
every n   1, we indicate Rn and Gn as the number of red and green balls,
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respectively, in the urn at stage n + 1. We are interested in the law of the
process of {Xn} and in the limit behavior of the quantities that are functions
of Rn and Gn, as, for example, the red balls proportion in the urn before the
n+ 1 stage defined as
Zn =
Rn
Rn +Gn
(2.1)
At the stage n   1, a ball is randomly chosen from the urn and replaced
together with other m   1 balls of the same color.
Now, let us examine the dynamics of the processes {Xn}, {Rn} and {Gn}.
{X1} is distributed as
Bernoulli
✓
r0
r0 + g0
◆
(2.2)
For every n   1, conditionally to X1, ...., Xn,
Xn+1 =
8>><>>:
0 with prob GnRn+Gn
1 with prob RnRn+Gn
(2.3)
where
(Rn+1, Gn+1) =
8>><>>:
(Rn, Gn +m) with prob
Gn
Rn+Gn
(Rn +m,Gn) with prob
Rn
Rn+Gn
(2.4)
One of the most important on the proportion of Z is expressed by the fol-
lowing
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Theorem 2.1.1. In a Polya Urn, when n goes to infinity, the red balls
proportion
Zn =
Rn
Rn +Gn
converges almost surely to a random limit.
Moreover, the limit distribution is a Beta( r0m ,
g0
m ).
2.2 Randomized Play-the-Winner Rule
The first application of a urn model in a clinical trial is due to Zelen
(1969), who exposed his theory in a paper on a rule winning (Play-the-
Winner-Rule) for controlled clinical trials. We want to run a clinical trial
in which two treatments, labeled as 0 and 1, are compared and patients are
accrued sequentially. The success or failure of the test result depends only
on the assigned treatment. In this way, the success of a treatment generates
another study on the same treatment with a new patient, while the failure
generates a study on the competitive treatment. Although the Zelen rule
is deterministic and, consequently, includes the typical biases of models not
randomized, it is noteworthy because it represents the first known case of
urn models used as sequential designs in clinical trials. His idea also inspired
later Wei and Durham (1978), which altering the original rule, have created
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a random strategy (Randomized Play-the-Winner Rule - RPW ).
In the original expression, we have Y0 balls of type A and B. Each time
that a patient is ready to be randomized, a ball is drawn and put back into
the urn. If we observe one A ball, it is assigned the corresponding treatment.
If the patient response is a success, then other balls of the same type are
added into the urn, while if it is register an unsuccessful, balls corresponding
to the opposite treatment are added into the urn.
Let NA,n be the number of patients to the treatment A, after n patients
are observed, and NB,n = n   NA,n. If pA = P {Success|TreatmentA},
pB = P {Success|TreatmentB}, qA = 1   pA and qB = 1   pB, then the
limit allocation NA,n/NB,n is qB/qA and it is a meausure of the relative risk
for n!1.
It can be noted how this rule was not built on the basis of some optimal
criterion and the allocation limit is not particularly attractive, as it tends
to be allocated according to the relative risk. Being the RPW a completely
randomized design, it benefits from the same characteristics of any random-
ized procedure. In particular, we do not expect a selection bias, but an
accumulation one (Rosenberger, 1996), given by those subjects who become
available to be recruited in the later stages of the study to benefit the impact
of previous results, as the first subjects have a higher likelihood of being
sent to treatment lower. For this reason it prefers a blind study, in which
CHAPTER 2. THE CLASSICAL URN MODELS 24
subjects do not know their succession in the study. However, in the studies
about emergency therapies, such as emergency surgery techniques, this type
of distortion is irrelevant.
Actually, it does resort to the use of RPW very rarely, as in the past has
raised strong criticism of the fact that in a clinical trial on ECMO therapy
(Bartlett et al., 1985) had been assigned to the control group only one subject.
Yao and Wei have tried to overcome this problem thinking to update the
structure of the urn only after a certain period. Furthermore, RPW has
been replaced by other adaptive strategies also in several survival studies
(Hallstrom et al. 1996, Rosenberger et al. 1997, Sverlov et al. 2014). So,
although in theory it would seem an ideal tool for clinical trials, in practice
it is good to think of other instruments.
Chapter 3
Reinforced Urn Model
As mentioned in the previous chapter, the RPW procedure has aroused a
lot of skepticism in practice. Among the many adaptive strategies in growth
in the last decade, we have focused on urn models that include a random
reinforcement. The idea is to vary the number of balls in the urn inserted
according to the responses of the patient, thus creating a proportion Z is
changed much faster than using the constant reinforcement. We are talking
about the so-called Randomly Reinforced Urn - (RRU). The RRUs were born
as an evolution of the Randomized Play the Winner Rule - (RPTW) and
have been introduced by Durham and Yu in 1990. Initially, it interested in
experiments with binary outcomes (success / failure) and were used mainly to
find the optimal dosage of a therapy. Subsequently, Muliere et al. (2006) and
Beggs (2005), have extended the application of the RRU also experimented
25
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with continuous responses.
3.1 The Model
Let us consider two treatments to be assessed, R and G. The subjects
come sequentially in the study and allocated to two treatments randomly,
according to a RRU design. The variables of interest are
• Allocations (Xi). The strategy used to assign subjects to one of two
treatments is through a process urn, which is supposed to be indepen-
dent of the answers.
• Treatments Responses (Yi). Random vectors i.i.d. with discrete or
continuous marginal distributions on <. It will be observed only one
answer for every patient.
• Reinforcement (U(Yi)). For each draw, after observing the response,
a variable number of balls is replaced into the urn following a proba-
bility distribution, called transformation function.
• Proportion (Z). The proportion of red balls is the parameter of the
Bernoulli r. v. of the color of the ball (allocation).
Now, we look at the description of the process. Let us consider an urn
containing a non-negative number of red (r0) and green (g0) balls, so that
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a red ball represents the treatment R and a green one the treatment G. We
impose the first condition
R0 = r0 and G0 = g0 (3.1)
from which we derive
D0 = R0 +G0 and Z0 = R0/D0 (3.2)
where D0 is the urn composition at time n = 0 and Z0 is the proportion of
red balls at same time.
Let us imagine that at time n = 1 one ball is drawn from urn and it
is observed the color. The color of the ball will be an independent random
variable of the answers equal to 1 if a red ball is drawn, equal to 0 if it is
a green ball, then it is a Bernoulli random variable with parameter equal
to the proportion of red balls, that is Bernoulli(Z0) distribution denoted by
X1.
Regarding the reinforcement distribution, we have to focus on the re-
sponses: if it is drawn a red ball, then it will be replaced with a random
number of the balls of the same color, depending on the previous responses.
Let M1 2 µ and N1 2 ⌫ be two independent r. v. representing the function
of the response variable on the ball drawn, and let suppose that M1, N1 and
X1 are independent. Subsequently, the ball drawn will be replaced into the
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urn with
X1M1 + (1 X1)N1
balls of the same color. M1 and N1 are the functions of the responses corre-
sponding respectively to the red and green balls, also called transformation
functions, because they capture the e↵ect of responses and turn it into ran-
dom reinforcement. The reinforcement, for example, could be linked to the
survival functions: the greater the survival, the greater the reinforcement,
and then the number of balls added in the urn. This implies that, if we
drawn a red ball, the urn will be reinforced by the r. v. M1, belonging to µ,
instead, if it is extracted a green ball, the urn will be reinforced by the r. v.
N1, belonging to ⌫. Generally, M1 and N1 are represented as
U(Yi(n+ 1))
where U is a monotonic function, which could be equal to an identity function
when the distributions of the responses have non-negative limited support.
The new composition of the urn will be equal to
R1 = R0 +X1M1
G1 = G0 + (1 X1)N1
D1 = R1 +G1
Z1 = R1/D1
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The process is iterated following the same rule. Each draw will be assigned
the patient to the treatment following the allocation strategy given by
Xn+1U(YR(n+ 1)) + (1 Xn+1)U(YG(n+ 1)) (3.3)
where Xn+1 is a Bernoulli r. v. with parameter
Zn =
Rn
Rn +Gn
and U(YR(n+ 1) =Mn+1 and U(YG(n+ 1) = Nn+1. The responses will be
Y (n) = XnYR(n) + (1 Xn+1)YG(n)
At the stage n + 1 we will have a sigma-algebra = generated by X1, ..., Xn,
M1, ...,Mn and N1, ..., Nn. The process will generate the following variables
Rn+1 = Rn +Xn+1Mn+1
Gn+1 = Gn + (1 Xn+1)Nn+1
Dn+1 = Rn+1 +Gn+1
Zn+1 = Rn+1/Dn+1
So, we have one finite sequence X = (Xn : n > 1) of Bernoulli r. v.,
where Xn is the color drawn at n-th time or, equally, the n-th allocation and
the process (Z,D) = ((Zn, Dn), n = 0, 1, 2, ...), where Dn is the total number
of the balls in the urn at time n and Z = (Zn : n > 0) the sequence of r. v.
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in [0, 1] representing the proportion of red balls present in the urn at each
step. The total number of the subjects will be
NR(n) =
nX
i=1
Xi
and
NG(n) =
nX
i=1
(1 Xi)
with NR(n)+NG(n) = n. Rn and Gn are the cumulative responses observed
and transformed by the utility function U , that is8>><>>:
Rn = r0 +
Pn
i=1XiU(YR(i))
Gn = g0 +
Pn
i=1(1 Xi)U(YG(i))
(3.4)
3.2 Asymptotic Results
At this point we show the reasons why the use of this strategy is optimal
for clinical studies. Recall that the main objective is to assign the highest
number of patients to the treatment superiors, that is to say that the prob-
ability of being assigned to the best treatment converges to one, so that the
proportion of the best treatment is asymptotically converged to one.
We distinguish now the average of the transformed response from non-
transformed, i. e. with no reinforcement e↵ect. We indicate the average
reinforcements of the urn as
mR =
Z
U(y)YRdy
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mG =
Z
U(y)YGdy
Li et al. (1996) proved the following very important result for the binary
responses. If mR > mG then
lim
n!1
Zn = 1
almost surely.
This result was then extended to the general case by Beggs (2005), Muliere et
al. (2006a) and Aletti et al. (2009a). Consequently, the contrary is also true:
the probability of assigning one patient to G treatment tends asymptotically
to 0. Based on this property, we try to apply this case in a trial in which
you want to demonstrate the e↵ectiveness of R respect to G when the first
treatment mean is bigger then the second one. Let us consider, then, the
finite mean responses from non-transformed random reinforcement, i. e.
µR =
Z
yYRdy
µG =
Z
yYGdy
It has to choose an appropriate transformation function, in the sense that
the following conditions must be simultaneously hold on
µR > µG if and only if mR > mG
µR = µG if and only if mR = mG
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ensuring in this way the convergence to the best treatment with probability
one when n! 1.
To decide which transformation function is the most appropriate is a del-
icate point, because it influences the rate of convergence and the distribution
of the allocations. Certainly, the best option should be one that takes into
account a good tradeo↵ between ethics and accuracy of the analysis. We
emphasize that, both in the case in which there is a superior treatment, and
both in the case where they are equal, the proportion of subjects designed
for the two treatments has the same limit of the composition of the urn
lim
n!1
NR(n)
n
= Z1 a. s.
and
lim
n!1
NG(n)
n
= 1  Z1 a. s.
Consequently, the proportion of subjects placed at the best treatment con-
verges to one. Let us now concentrate on the more delicate case: when the
means responses are the same how it will be the behavior of the proportion
Z? Recalling the achievements Muliere et al. (2006a), we know that the
process is a limited super or sub martigale. When the treatments give the
same results, the sequence of the proportion
Zn : n   0 converges a. s. to the random limit Z1 in [0, 1].
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The delicate point of this condition is that, until now, the distribution of Z1
is unknown. According to the results obtained by Aletti et al. (2007, 2009a),
we are only sure about that, under certain conditions, its distribution will
continue. In general, the problem of equality of the responses is particularly
important when you have to test e↵ectiveness of treatments under the null
hypothesis that these are equal. In fact, there are special cases studied in
the literature in which the distribution of Z1 is known.
Now, we can sum up all the considerations.
1. The responses distributions are the same. When YR = YG then
even distributions of reinforcement will be the same, U(YR) = U(YG) =
 . If responses to treatment are random variables constant, that is,   is
a grounding point, the RRU degenerates to the classic design of Polya
(Eggenberger, Polya, 1923): an urn initially contains r red balls and g
green balls and the reinforcement It is a constant m. In this case the
distribution of Z1 we know that is a Beta(r/m, g/m).
2. Random reinforcement di↵erent for success and failure. If in
a RRU design, we define the random reinforcement as a non-negative
number m for the success and zero for the failure, the distribution of
Z1 is still a Beta. It is about a result which follows from Aletti et al.
(2007) in which it is shown that the distribution of Z1 doesn’t change
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when U(YR) 6= U(YG).
It should be noted that when the treatments are equal, the moments higher
than the first of the reinforcements are di↵erent
Z
U(y)hYRdy 6=
Z
U(y)hYGdy for h > 1
In this case, although the treatments are equal, the distributions of the re-
inforcements are di↵erent.
3.3 Inference
Let us consider the case where we want to estimate mean {µR, µG} and
variance { 2R,  2G}of the distributions of the responses. Following the method
of May and Flournoy (2009), we define the estimators based on the observed
responses of the n subjects with a random sample size NR(n) and NG(n)
YˆR(n) =
⌃ni=1XiYR(i)
NR(n)
YˆG(n) =
⌃ni=1(1 Xi)YG(i)
NG(n)
 ˆ2R(n) =
⌃ni=1Xi(YR(i)  YˆR(n))2
NR(n)
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 ˆ2G(n) =
⌃ni=1(1 Xi)(YG(i)  YˆG(n))2
NG(n)
.
In May et al. (2012) it proves the strict consistency of YˆR(n), YˆG(n),
 ˆ2R(n) and  ˆ
2
G(n) for µR, µG,  
2
R and  
2
G respectively. Furthermore, the two
estimators are asymptotically jointly distributed as Normal, despite of the
randomness of NR(n) and NG(n), its dependence and the no convergence of
NR(n)
n and
NG(n)
n to a constant in (0, 1). Now suppose you want to build a
hypothesis tests on the means.
H0 : µR = µG versus H1 : µR > µG.
In the literature there are cases in which the asymptotic normality occurs
only when the proportion of allocations converges to a fixed ⇢ 2 (0, 1) and
cases applicable to the RRU in general, that is, when both the averages are
the same and when both are di↵erent.
A work worthy of attention is the paper of Paganoni and Secchi (2007),
in which it is presented a new guideline to compare an adaptive design with
one no adaptive, i. e. one balanced study. At the end of the paper, you can
find the regions useful for discriminating the use of either strategy. These
considerations have been e↵ectively used for the comparison of two studies
adaptive (Bandyopadhyay and Biswas, 2001; Biswas and Basu, 2001).
Chapter 4
Modified Reinforced Urn
Model
In recent years, the RRU models have become under study, in particular,
has aroused our curiosity a change made in 2013 by Ghiglietti, Aletti and
Paganoni. Significant steps have been made with regard to the convergence
of the proportion of balls. One of the first results will be presented, in fact,
the convergence theorem. The most important change is the introduction
of two thresholds in which falls the allocation proportion. Practically, the
previously values 0 and 1 are replaced with the thresholds. The main reason is
that we want to avoid a concentration of one color of balls and, in particular,
the extreme case where the composition of the urn asymptotically collapses
towards a type of ball which, as we have seen before in the case of RPW,
36
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turns out to be not attractive in practice of clinical studies.
4.1 The Model
Let us imagine that we are in a clinical trial in which you want to compare
two treatments R and G. The subjects in the study sequentially enter and are
allocated to the two treatments randomly, according to a Reinforced Modified
Random Urn - (MRRU) design. The variables of interest are the same of the
RRU model, but with a modification in the reinforcement process.
Let us consider an urn containing a non-negative number of red (r0) and
green (g0) balls, so that a red ball represents the treatment R and a green
one the treatment G. At time 0 the process will be
R0 = r0, G0 = g0, D0 = R0 +G0, Z0 = R0/D0. (4.1)
At time n = 1, one ball is drawn from the urn and its color is a Bernoulli(Z0)
X1 = 1[0,Z0](U1)
Let M1 and N1 be two independent random variables having distributions
µR and µG with the support on [↵,  ], where 0 6 ↵ 6   < 1. These
variables represent the responses to the treatments R and G, where (U1) is a
sequence of independent Uniform r. v. in (0, 1). Moreover, we assume that
X1, M1 and N1 are independent. Now, we have in this situation a di↵erent
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type of reinforcement, including two limit thresholds to avoid an excessive
concentration of red balls. We could have 4 di↵erent scenarios. If we drawn
one red ball, then it will be replaced into the urn with a random number
X1M1 of the same balls if Z0 < ⌘, with ⌘ 2 (0, 1) a parameter decided a
priori. Otherwise, the urn composition doesn’t update. Instead, when we
drawn one green ball, it will be replaced into the urn with a random number
(1 X1)N1 balls of the same color only if Z0 >  , with   < ⌘ 2 (0, 1); on the
contrary nothing changes. The updating process then becomes
R1 = R0 +X1M11[Z0<⌘],
G1 = G0 + (1 X1)N11[Z0> ],
D1 = R1 +G1,
Z1 = R1/D1.
As we can see, while in the previous case there was always an update of the
urn, now sometimes we could find in deadlock situations in which there shall
be no adjustment to the process. This happens when   < Z0 < ⌘. Now, we
can iterate infinite the strategy and at time n + 1, given the sigma-algebra
Fn generated by X1, ..., Xn, M1, ...,Mn and N1, ..., Nn, the new process will
be
Rn+1 = Rn +Xn+1Mn+11[Zn<⌘],
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Gn+1 = Gn + (1 Xn+1)Nn+11[Zn> ],
Dn+1 = Rn+1 +Gn+1,
Zn+1 = Rn+1/Dn+1.
We have, thus, generated an infinite succession of X = (Xn, n = 1, 2, ...)
Bernoulli r. v., with Xn equal to the color of the drawn ball at time n, and
one process (Z,D) = ((Zn, Dn), n = 0, 1, 2, ...) with values in [0, 1]⇥ (0,1),
whereDn represents the total number before the n th ball was drawn and Zn
is always the proportion of red balls. X will be the color process generated
by the urn, and (Z,D) the process of its composition. We highlight that
(Z,D) a Markov sequence respect to the filtration Fn.
As mentioned above, also for the convergence it has been achieved an
important result. Infact, we have the following
Theorem 4.1.1 (Aletti et al.). The sequence of the proportions Z = (Zn, n =
1, 2, ...) of the MRRU process converges almost surely to the following limit
lim
n!1
Zn =
8>><>>:
⌘ if
R  
↵ xµRdx >
R  
↵ xµGdx
  if
R  
↵ xµRdx <
R  
↵ xµGdx
For the proof we refer to Aletti, Ghiglietti, Paganoni (2013).
The strength of this result is not only the proof of the convergence of pro-
portion, but the fact that when this convergence exists we know what that
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is, and its value is exactly equal to the two thresholds introduced in the
construction of the urn process with random reinforcement.
The two thresholds, defined in advance at the beginning of the study and
decided based on the experience of the researcher, are nothing more than
a fixed target of allocation, introduced to avoid extreme cases where the
proportion collapses to 1 or 0. Note that we are evaluating probability dis-
tributions with di↵erent means, then treatments with well-defined outcomes.
A further advantage of the introduction of two thresholds is that the prob-
ability of allocation of patients to di↵erent treatments can be chosen by the
researcher in order to ensure full control of the evolution of the urn. However,
at this juncture nothing it is said on the speed of convergence, aspect that
will be treated in the simulation, in which will be taken a higher number of
urns to increase the convergence’s speed.
As regards the case in which means are equal, that is the two treatments
are perceived as similar, a result was achieved by the following
Lemma 4.1.2. We assume that mR = mG = m. If D0 > 2 , then
E
✓
sup
n
|An
◆
6  
D0
E (hMi1   hMin|Fn) 6  
D0
, 8n   0.
Consequently, we have
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Lemma 4.1.3. We assume that mR = mG = m. D0 > 2 , then
P
✓
sup
n
|Zn   Z0|   h
◆
  
D0
✓
4
h2
+
2
h
◆
8h > 0.
In general, when the means are equal, that is when the treatments have
the same e↵ects, we don’t have the explicit form of the asymptotic distribu-
tion of proportion Zn. The only important information that we know is that
the proportion converges to a continuous distribution.
In some special cases, however, we can know what is the distribution of
responses (Flournoy, May, Secchi, 2012). Saying that the distribution of the
responses are equal is the same to say that the distribution of the reinforce-
ment is equal. When the distribution of responses and reinforcements are
equal to a discrete distribution, the responses to the treatment have a con-
stant reinforcement, then the RRU degenerates to classical Polya Urn. In
this case we already shown that Z1 follows a Beta(r/m, g/m). We have the
same result also for the RRU in the case of binary responses, where m is the
random number of balls added when success happens and 0 when we have a
failure (Aletti, 2007).
It should be noted that when the treatments are perceived equally, in the
sense of having the same mean responses, the moments higher than the first
of the reinforcements are di↵erent. This consideration may be of interest
when the treatments are identical, but the distributions of the reinforcement
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not. The conclusion we reach is that the total number of balls increases
exponentially: this result depends on the reinforcements, then the balls that
are adding to the urn, which are random in the sense that change based on
the responses from patients. We have to underline the fact that the number
of balls will never decrease because the ball drawn, in any color, it will always
be reinserted into the urn, with or without reinforcement by using the upper
and lower thresholds. The goodness of a treatment is identified with its
expected value, or mean. The greater the mean of the responses, the better
the treatment and the greater the reinforcement in terms of balls added to
the urn, so as to reach at the end the convergence at the upper end.
4.2 Convergence Theorem: some simulations
Now let us see how to use in practice the convergence theorem presented
before, based on the idea proposed by Aletti et al. (2011). An interesting
way is to use it for finding the mean of the responses of one treatment in a
two arms clinical trial. We imagine that you want to design a clinical trial
in which we know only one treatment R and we want to figure out the mean
e↵ect on patients of the introduction of a new treatment G. In statistical
terms, we want to know the mean of the distribution of the responses of
patients to the new treatment. Knowing well the competitive treatment
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allows us to make adjustments during the trial and change the mean of
treatment R properly.
Let us considerK urns with the same unknown initial composition (r0, g0).
We use a greater number of urns because we want to see faster the empirical
convergence. As before, the red ball is associated to the known treatment
R, the new treatment to the green G. We indicate with Zj = (Zjn)n2N the
process of the proportion in the j-th urn, with j 2 {1, 2, ..., K}. For every
urn, the convergence theorem says us
lim
n!1
Zn =
8>><>>:
⌘ if mR > mG
  if mR < mG
Now, we see that we can use the result of convergence for the MRRU
model to estimate the mean mG when this is unknown and it is instead
known mR. For this purpose, it will be su cient to repeat several times
the simulation with di↵erent values of mR, at each step the simulation is
calculated by the empirical cumulative function Fˆ and evaluated as the
Wasserstein distance between it and the three sample functions F (x) = 1x> ,
F⌘(x) = 1x>⌘ and the cumulative function Fe of the asymptotic distribution
that is obtained in the case of reinforcements with the same mean mR. Given
that we unknow the latter is not known except for some case particularly
(when, for example , the reinforcements are constant we know that Z1 is a
Beta(r0/m, g0/m) we have empirically determined this function run an other
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simulation. When the Wasserstein distance between the function and one of
the empirical cumulative functions sample becomes less of a tolerance ↵ fixed
a priori, the simulation ends. In such case there will be one of the following
situations:
• the sample function with the Wasserstein distance minimum is F , then
mR < mG. It will proceed with the experiment, and then will be
performed another simulation in which the reinforcements of red balls
will have the mean mR greater than that used for this iteration;
• the sample function with the minimumWasserstein distance is F⌘, then
mR > mG. It will be performed another simulation in which the re-
inforcements of red balls will have mean mR lower than that used for
this iteration;
• the sample function with the minimum Wasserstein distance is Fe, this
happens when mR v mG. Only in this case we can terminate the
experiment, since we have found an estimate of mG.
We performed two types of experiments using the first as a normal distribu-
tion reinforcements variance always equals equals 1, and the second constant
reinforcement (classical Polya Urn). The next figures show the results pro-
duced in the two cases. In both situations they are taken mG = 17 and
mR = 30, 20, 15, 17.5.
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Figure 4.1: Normal Reinforcement,mR = 30,mG = 17,   = 0.3, ⌘ = 0.7, r0 =
w0 = 200
In both experiments, it is observed that for mR = 30, 20 the function that
realizes the minimum Wasserstein distance is F⌘, in the case mR = 15, the
minimum is realized by F , in the case mR = 17.5 the minimum distance is
obtained by Fe.
In conclusion we have seen that thanks to the convergence theorem we
can calculate the unknown mean, regardless of the assumptions imposed on
the reinforcements. The fact remains that, as anticipated above, in the case
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Figure 4.2: Normal Reinforcement,mR = 20,mG = 17,   = 0.3, ⌘ = 0.7, r0 =
w0 = 200
of reinforcements constants, and therefore the case of the Classical Polya
Urn, the distribution of the proportion of the balls is known to be a Beta
distribution, but this is not proved for MRRU model.
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Figure 4.3: Normal Reinforcement,mR = 15,mG = 17,   = 0.3, ⌘ = 0.7, r0 =
w0 = 200
4.3 Hypothesis Tests
A very important aspect concerns the power of hypothesis testing and
the determination of the sample size. Suppose that we run a clinical trial
in which patients were assigned n0 to two treatments R and G, with p0 the
proportion of patients assigned to R. We want to test the hypothesis
H0 : mR = mG
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Figure 4.4: Normal Reinforcement, mR = 17.5, mG = 17,   = 0.3, ⌘ =
0.7, r0 = w0 = 200
versus
H1 : mR 6= mG
with significance level equal to ↵. From the theoretical results we know that
the statistic
⇣0 =
X¯R   X¯G   (mR  mG)q
 2R
NR
+
 2G
NG
,
where NR and NG are the patients assigned to treatment R and G, respec-
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Figure 4.5: Constant Reinforcement, mR = 30, mG = 17,   = 0.3, ⌘ =
0.7, r0 = w0 = 200
tively, and
XR =
⌃ni=0XiMi
NR
,
XG =
⌃ni=0(1 Xi)Ni
NG
,
are distributed ad a standard Normal. Then, the critical region of level ↵ is
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Figure 4.6: Constant Reinforcement, mR = 20, mG = 17,   = 0.3, ⌘ =
0.7, r0 = w0 = 200
represented by
R↵ =
8<:|XR  XG| >
s
 2R
NR
+
 2G
NG
· z↵/2
9=; .
In general, one di↵erence  0 between two treatments is clinically relevant if
it is greater than a fixed quantity. We denoted by 1  0 the minimum power
of the test we want to achieve at  0. We we have fixed ↵,  0, knowing p0
and n0, we can compute the unique value of  0.
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Figure 4.7: Constant Reinforcement, mR = 15, mG = 17,   = 0.3, ⌘ =
0.7, r0 = w0 = 200
For example, we impose ↵ = 0.05,  0 = 0.2, p0 = 0.5, n0 = 198, then we
have 1   0 = 0.8.
Now, we want to undestand how finding a new test (n, p) so that it is
uniformly most powerful test (p0, n0) and that it assigns less patients to the
worse treatment. One can verify that this happens when the pair (p, n) is
located in one of these following three regions.
A REGION In this region the tests are uniformly most powerful test (p0, n0)
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Figure 4.8: Constant Reinforcement, mR = 17.5, mG = 17,   = 0.3, ⌘ =
0.7, r0 = w0 = 200
and fewer patients assigned to treatment R
A =
⇢
(p, n) 2 (0, 1)⇥ (0,+1) : n (p) < n < p0n0
p
 
,
where n (p) is defined as the following reasoning. Called popt =
 R
 R+ G
,
n (p) =
✓
p2opt
p
+
(1  popt)2
(1  p)
◆
·
✓
p2opt
n0p
+
(1  popt)2
n0(1  p)
◆ 1
.
B REGION The tests in this region are uniformly most powerful of the
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Figure 4.9: Power of the test of the mean di↵erence when ↵ = 0.05,  0 = 0.2,
p0 = 0.5, n0 = 198
test (p0, n0) and they assign fewer patients to either treatment
B =
⇢
(p, n) 2 (0, 1)⇥ (0,+1) : n > max
⇢
p0
p
,
1  p0
1  p
 
· n0
 
(4.2)
C REGION The tests in this region are uniformly most powerful of the
test and assign less patients to treatment G
C =
⇢
(p, n) 2 (0, 1)⇥ (0,+1) : n (p) < n < (1  p0) · n0
1  p
 
,
It is clear that the allocation of patients to the two treatments should be
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made so that, if mR < mG, (p, n) 2 A, if instead mR < mG, then (p, n) 2 C.
In this way it can use an allocation method based on an MRRU urn, with  
and ⌘ appropriately chosen.
Figure 4.10: A, B, C regions when n0 = 198, p0 = 0.5,  R =  G = 0.5
Doing the test we find that when n = 300, n0 = 198, p0 = 0.5, then it has to
be
  2 [0.2084512, 0.33] ⌘ 2 [0.67, 0.7915488]
To verify empirically the properties of this test, we run K = 200 urn pro-
cesses with intervals [ 1, ⌘1] = [0.33, 0.67] and [ 2, ⌘2] = [0.2084512, 0.7915488].
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To do this we have run K urn processes and, using the properties exposed
before, compute the mean power (the mean of all the powers obtained by
all the K test when   = |mR  mG|), the empirical power (the mean of the
results of the K test computed assuming of assigning 0 when the hypothesis
H0 is accepted, 1 when the hypothesis H1) and the times in which the power
of each test was higher than the power of the test classic.
We run the simulation, assuming K = 200, mR = 1.25, mG = 1, and
we see that for both intervals the ”improved” power (number of times in
which the power of the new test was superior to that of the reference test) is
1. Moreover, we register the following the results registered in the table 4.1.
Interval Calculated Power Empirical Power Mean NR Mean NG
[ 1, ⌘1] 0.9760361 0.9 127 122
[ 2, ⌘2] 0.9905799 0.91 157 143
Table 4.1: Di↵erent values of   and ⌘
4.4 RRU versus MRRU
At this point we are able to make some comparisons between the two
methods proposed. First of all, we have carried out simulations to see the
CHAPTER 4. MODIFIED REINFORCED URN MODEL 56
Figure 4.11: Patients assigned to the treatments R and G when [ 1, ⌘1]
Figure 4.12: Patients assigned to the treatments R and G when [ 2, ⌘2]
di↵erent trend of the proportion of red balls depending on whether you are
in the case where the thresholds are present or not. Initially we performed
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simulations using three di↵erent distributions for the reinforcement: normal,
exponential and constant reinforcements. With this choice, it was verified
empirically that the convergence results seen previously for the two urn pro-
cesses does not depend on the particular distribution of the reinforcements,
but only by their mean. In all cases, it is taken as an initial composition of
the urn r0 = 200, g0 = 200.
The figures 4.13, 4.14 and 4.15 report the graphs in the case without
thresholds, that is with   = 0 and ⌘ = 1, the numerical simulations for 10000
extractions with reinforcements following normal distribution.
In the figures 4.16, 4.17 and 4.18, we present the results obtained with
inserting the thresholds, in particulare we impose   = 0.3 and ⌘ = 0.7.
As we can see in the figures above, consistent with the theoretical results,
when we run the RRU model the sequence Zn converges to 0 if mR < mG,
to 1 if mR < mG, instead when we run the MRRU model the sequence
Zn converges to   if mR < mG, to ⌘ if mR < mG. When, instead of the
means of reinforcements are equal, the result is ambiguous. To better assess
what happens when the averages are equal, we have modified the functions
used in the simulations presented before for K independent urns. In this case
listed the histograms for the di↵erent distributions of the reinforcements. We
show only the results for the RRU model, first with constant reinforcements
(figures 4.19, 4.20 and 4.21), and after with normal reinforcement (figures
CHAPTER 4. MODIFIED REINFORCED URN MODEL 58
Figure 4.13: Normal Reinforcement with mR = 4 and mG = 2 for 10000
drawings
4.22, 4.23 and 4.24).
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Figure 4.14: Normal Reinforcement with mR = 2 and mG = 4 for 10000
drawings
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Figure 4.15: Normal Reinforcement with mR = mG = 3 for 10000 drawings
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Figure 4.16: Normal Reinforcement with mR = 4 and mG = 2 for 10000
drawings,   = 0.3 and ⌘ = 0.7
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Figure 4.17: Normal Reinforcement with mR = 2 and mG = 4 for 10000
drawings,   = 0.3 and ⌘ = 0.7
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Figure 4.18: Normal Reinforcement with mR = mG = 3 for 10000 drawings,
  = 0.3 and ⌘ = 0.7
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Figure 4.19: Constant Reinforcements, mR = 2, mG = 4, r0 = g0 = 200, 500
urns.
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Figure 4.20: Constant Reinforcements, mR = 4, mG = 2, r0 = g0 = 200, 500
urns.
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Figure 4.21: Constant Reinforcements, mR = 3, mG = 3, r0 = g0 = 200, 500
urns.
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Figure 4.22: Normal Reinforcements, mR = 2, mG = 4, r0 = g0 = 200, 500
urns.
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Figure 4.23: Normal Reinforcements, mR = 4, mG = 2, r0 = g0 = 200, 500
urns.
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Figure 4.24: Normal Reinforcements, mR = 3, mG = 3, r0 = g0 = 200, 500
urns.
Chapter 5
Real Case: The Melatonin
Study
In this chapter we are going to evaluate the models exposed before in the
real context. As we proved in first chapters, the urn models work well in
the simulation, now we want to see their behavior in the practical context.
In the next sections, we present the results obtained after applied the urn
designs to one real experiment.
In this chapter we use the dataset from the study ”Melatonin reduces the
need for sedatives in high-risk critically ill patients” conducted in the ”San
Paolo Hospital - University Campus”, Milan, by the Doctors Iapichino G.
and Mistraletti G., from Institute of Anesthesiology and Intensive Care. A
single-center, double-blind randomized placebo-controlled trial was carried
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out from July 2007 to May 2010. We use the information gathered from
this study to re-design a new imaginary trial in which we use the Response
Adaptive Design.
5.1 The original study
The original study is aimed to estimate if the administration of oral mela-
tonin in ICU patients is able to regularize the sleep-waking rhythm, improv-
ing sleep quality and reducing episodes of agitation/mental confusion.
The main objectives are: assessment of sleep quality, prevalence of mental
confusion/agitation, amount of daily sedative drugs administered and mod-
ification of redox status. The primary outcome measures is the overall
sedatives daily doses. The secondary outcome measures are: prevalence
of delirium assessed with CAM-ICU, prevalence of mental disorders, ICU
length of stay, ICU mortality, hospital mortality, sleep quantity assessed by
wrist actigraphy.
At the admission in ICU, obtained the informed consent, the patients,
who were high-risk critically ill, will be randomly assigned to the ”Treatment”
group receiving melatonin 3mg BID by oral route (or nasogastric tube) or
to the “Control” group receiving placebo. The sedation will be performed
according to clinical standard.
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The study was a randomized, controlled, double-blind. Of the 1158 pa-
tients admitted to ICU and treated with conscious enteral sedation, 82 crit-
ically ill with mechanical ventilation ¿ 48h and Simplified Acute Physiology
Score II ¿ 32 points were randomized 1:1 to receive, at eight p.m. and mid-
night, melatonin (3+3mg) or placebo, from the third ICU day until ICU
discharge.
The results of the analysis have shown that melatonin treated patients
received lower amount of enteral hydroxyzine. Other neurological indicators
(amount of some neuroactive drugs, pain, agitation, anxiety, sleep observed
by nurses, need for restraints, need for extra sedation, nurse evaluation of se-
dation adequacy) seemed improved, with reduced cost for neuroactive drugs.
Post - traumatic stress disorder prevalence did not di↵er between groups, nor
did ICU or hospital mortality. There are some study limitations, including
the di↵erences between groups before intervention, the small sample size, and
the single-center observation.
They concluded that long term enteral melatonin supplementation may
result in a decreased need for sedation, with improved neurological indicators
and cost reduction. Further multicenter evaluations are required to confirm
these results with di↵erent sedation protocols.
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5.2 The ICU trial on Melatonin reinterpreted
according to RRU Model
We have re-designed the study and resorted a way of allocation using the
urn with random reinforcement studied previously. The two objectives that
we set were:
1. determine the best treatment,
2. minimize (maximize) the patient’s number with the worst (best) treat-
ment.
We know that, in this case, patients come sequentially in the experiment
and each time a new subject arrives, a ball is drawn and the patient is as-
signed to one of two treatments, based on the color of the ball that represents
the treatment. In our case, we indicate red balls for the melatonin (R treat-
ment) and green balls for the placebo (G treatment). Later, we will see the
response to the assigned treatment and we will replace in the urn other balls
of the same color of the drawn one, whose quantities will be a function of the
observed response. We repeat the procedure until of the next patient. In this
way, the composition of urn changes every time a new response is observed,
and then with it the probability of allocating of patients to treatments.
To achieve the first goal we use the bootstrap method and run 200 sim-
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ulations of the responses from the empirical distribution obtained by the
responses of the original study. As you can see from Figure 5.1, the urn
process is able to identify the best treatment. Particularly, among the sim-
ulations we ran, 169 times the urn assigned the largest number of patients
to melatonin (the best treatment), and only 31 times to placebo treatment.
Moreover, the proportion of the R balls representing the melatonin treatment
tends to 1, in particular to 0.98. Then, also the convergence is assured.
Figure 5.1: Number of patients assigned to placebo treatment (G) and mela-
tonin treatment (R) with RRU method.
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The second goal is to compare the performance statistics of the original
clinical trial, that was randomized controlled, with those of a test based on
RRU design. Now, we want to show that a response adaptive clinical trial
is able to lead to a statistical test as the most powerful and to assign less
patients to the less e↵ective treatment, in our case the placebo group.
We considere three cases, based on a di↵erent sample sizes: sample =
82, sample = 102, sample = 122. For each of these cases, we run 10000
simulations of the experiment. In each simulation, we have a virtual urn
whose drawings set the assignments of patients to treatments, and in general,
the two sample sizes at the end of the experiment will be di↵erent every
time. The patients responses to treatments, that are used to update the
urn’s composition, are randomly drawn from the data collected for testing
with the randomization controlled. The RRU design generates two samples
with di↵erent numerosity in the di↵erent experiments.
In Figure 5.2 we reported the boxplots for the number of patients as-
signed to the lower treatment (placebo - G) in the three cases with di↵erent
sample sizes. As we can notice, in all the three cases, more than 50 per-
cent of the times the adaptive model assigns fewer patients to treatment G.
Moreover, this happens even when the number of total patients used in the
experiment is greater than the original one. For each simulation performed,
we have realized a t - test at the significance level of 5 percent to test whether
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the mean di↵erence was significantly di↵erent in the two samples (Placebo
vs Melatonin).
For each scenario, we reported the power of the test obtained as the pro-
portion of the number of times that the test has encountered such di↵erence
between the means. In Figure 5.2, each power is been shown under the
corresponding boxplot and next to each boxplot we have shown the patient’s
number for each group in the balanced trial. We have calculated the power
of the original test obtained by the method of the randomization controlled,
equal to 0.8. This value is calculated evaluating the theoretical power func-
tion of the t- tests at the values of the observed sample means. We can
therefore see that in second and third case, the response adaptive model is
able to build a statistical test with a power equal to or greater than the
original test.
After all these considerations, we can conclude that the RRU method
confirms the theoretical results also in practice.
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Figure 5.2: Boxplots of the number of patients assigned to lower treatment
(placebo) in the three cases: sample size = 82, sample size = 102, sample size
= 122. Next to each boxplot it is indicate the number of patients assigned
in the classical controlled trial. Below is shown the power of the test to the
adaptive response obtained in the simulation.
Chapter 6
Conclusions
In this thesis we interested in the use of adaptive models in clinical trials,
especially on the strategies based on the urn models. These techniques used
not only for binary responses, but also for the continue ones. We have seen
that the use of these methods allows to maintain a certain degree of ran-
domization, useful for the purposes of statistical analysis. Starting with the
Polya’s Urn, we analyzed the main changes, focusing on designs with random
reinforcement. In this case the urn has the ability to change its composition
depending of the reinforcements, that is, the e↵ects of the treatments on the
patients. This means that all patients will be allocated to the asymptoti-
cally best treatment, thereby o↵ering subjects in the sample the best care
among those in the study. Our analysis focused on those models that have
an asymptotic target set for the proportion urn. This value represents the
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limit to which the proportion of patients assigned to di↵erent treatments in
the study, will converge asymptotically.
Although these models exhibit many advantages, one of the weaknesses
is the delay of the answers that could lead to an increase in time analy-
sis. Di↵erent solutions may be used: resorting to a multi-center trial, using
a Bayesian approach considering the distribution of answers as a priori or
considering the covariates.
A number of scientific questions arise with the use of Bayesian Adaptive
Randomization (BAR). Because the variability of an estimator of a compar-
ative e↵ect between the two treatments is lower when there is balance in
allocations, especially in the case of BAR, the ethical goal is in contrast with
that of optimizing the statistical accuracy.
Another weakness is the fact that the characteristics of the patients in the
study could change systematically over time, a phenomenon known as ”drift”,
and this could cause a impractical procedure. While the use of a model for
covariates reduces the probability of this problem, the drift caused by the
e↵ects of latent variables is a very delicate aspect. In regards to this several
methods were created to manage ”drift” (Karrison et al. 2003). In general,
a very controversial and typical issue in the design of a Bayesian clinical trial
is the choice of the prior distribution.
It is this approach that we decided to follow to continue our research.
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In fact, an evolution of these adaptive models in Bayesian key are being
studied, mainly thanks to the recent period at Department of ”Biostatistics
and Computational Biology” of the Harvard T.H. Chan School of Public
Health, working with the group of Professor Parmigiani and Professor Trippa.
We started working on a new adaptive model that combines cross-over design
, thus taking into account the possibility for a person to change treatment,
and Bayesian Adaptive Randomization. The aim is to define the method to
be able to compare with the design of the urn models and to generalize these
methods to a multiarm clinical trial with continous responses.
So, this is only the springboard to new insights. It is not one ending, but the
new starting.
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R Code
.1 RRU versus MRRU
In this appendix we report the R code used for all the simulation in this
thesis.
The following one_step make a step from the process urn, when we know
the current composition of the urn and a set of parameters that define the
type of reinforcement to be applied.
one_step = function(r, g, mr, mg, tipo_rinforzo, delta, eta) {
z = r / (r + g);
x = rbinom(1, 1, z);
if(tipo_rinforzo == ’n’) {
m = rnorm(1, mr);
n = rnorm(1, mg);
} else if (tipo_rinforzo == ’c’) {
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m = mr;
n = mg;
} else if (tipo_rinforzo == ’e’) {
m = rexp(1, mr);
n = rexp(1, mg);
}
if(z < eta)
r = r + x*m;
if(z > delta)
g = g + (1-x)*n;
z = r / (r + g);
cat("Palline rosse: ", r, "\n");
cat("Palline bianche: ", g, "\n");
cat("Proporzione: ", z, "\n");
return(c(r, w, z));
}
The function simulation simulates an entire urn process calling up the
function one_step
simulation = function(r0, g0, mr, mg, n_iterazioni, +
+ tipo_rinforzo, delta = 0, eta = 1) {
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r = r0;
g = g0;
proporzione = rep(0, n_iterazioni);
for(i in c(1 : n_iterazioni)) {
output = one_step(r, g, mr, mg, tipo_rinforzo, delta, eta);
r = output[1];
w = output[2];
proporzione[i] = output[3];
}
windows();
plot(proporzione, type=’l’, ylim = c(0, 1), +
+ main=paste(’Simulazione di ’, n_iterazioni, ’ estrazioni’), +
+ xlab = "", ylab = "Zn");
abline(h=delta,col=’blue’)
abline(h=(eta+delta)/2,col=’red’)
abline(h=eta,col=’blue’)
}
We note that the two functions lend themselves to run simulations using
three di↵erent distributions for the reinforcements: normal reinforcements,
exponential reinforcements and constant reinforcements, depending on the
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value assumed by the parameter tipo_rinforzo. With this choice, we want
verify empirically that the convergence results, seen previously for the two
processes urn, do not depend on the particular distribution of the reinforce-
ments, but only by their means.
.1.1 Di↵erent independent urns
The following are the modified functions for k independent urns.
one_step_vectors = function(r, g, mr, mg, tipo_rinforzo, delta, eta) {
z = r / (r + g);
k = length(r);
if(tipo_rinforzo == ’n’) {
m = rnorm(k, mr);
n = rnorm(k, mg);
} else if (tipo_rinforzo == ’c’) {
m = rep(mr, k);
n = rep(mg, k);
} else if (tipo_rinforzo == ’e’) {
m = rexp(k, mr);
n = rexp(k, mg);
}
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x = rep(0, k);
for(i in c(1:k)) {
x[i] = rbinom(1, 1, z[i]);
if(z[i] < eta)
r[i] = r[i] + x[i]*m[i];
if(z[i] > delta)
g[i] = g[i] + (1-x[i])*n[i];
}
cat("Palline estratte: ", x, "\n");
cat("Palline rosse: ", r, "\n");
cat("Palline bianche: ", w, "\n");
z = r / (r + w);
cat("Nuova composizione delle urne: ", z, "\n");
return(list(r, g, z));
}
and
simulation_vectors = function(r0, g0, mr, mg, n_iterazioni, tipo_rinforzo, +
+ k, delta = 0, eta = 1) {
r = rep(r0, k);
g = rep(g0, k);
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proporzione = matrix(nrow = k, ncol = n_iterazioni);
for(i in c(1 : n_iterazioni)) {
output = one_step_vectors(r, g, mr, mg, tipo_rinforzo, delta, eta);
r = output[[1]];
w = output[[2]];
proporzione[, i] = output[[3]];
}
hist(proporzione[,n_iterazioni], col = "blue", +
+ main=paste(’Simulazione di ’, n_iterazioni, ’ estrazioni per ’, k, " urne"), +
+ xlab="", ylab="", xlim=c(0,1))
}
.1.2 Application of Convergence Theorem
We shown below the code for the application of the Convergence Theorem.
simulation_test = function(r0, g0, mr, mg, tipo_rinforzo, alpha = 0.001,
+ passo = 0.01, n_iterazioni = 10000, k = 500, delta = 0, eta = 1) {
r = rep(r0, k);
g = rep(g0, k);
ascisse = seq(from=0, to=1, by=passo);
F_delta = ifelse(ascisse >= delta, 1, 0);
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F_eta = ifelse(ascisse >= eta, 1, 0);
F_e = fe(r0, g0, mr, tipo_rinforzo, passo, delta, eta);
F = rep(0, length(ascisse));
errore = 1;
j = 0;
while(errore > alpha && j < n_iterazioni) {
j = j + 1;
output = one_step_vectors(r, w, mr, mw, tipo_rinforzo, delta, eta);
r = output[[1]];
w = output[[2]];
z = output[[3]];
for(i in c(1:length(ascisse))) {
F[i] = (sum(z < ascisse[i])) / k;
}
int1 = passo*sum(abs(F - F_delta));
int2 = passo*sum(abs(F - F_e));
int3 = passo*sum(abs(F - F_eta));
errore = min(int1, int2, int3);
}
par(mfrow=c(1,3));
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plot(ascisse,F_delta,type = ’n’, ylab = ’’, xlab = ’’)
lines(ascisse, F_delta)
lines(ascisse, F)
polygon(c(ascisse, rev(ascisse)),
+ c(F_delta, rev(F)), col = "blue", border = NA)
plot(ascisse,F_e,type = ’n’, ylab = ’’, xlab = ’’)
lines(ascisse, F_e)
lines(ascisse, F)
polygon(c(ascisse, rev(ascisse)),
+ c(F_e, rev(F)), col = "blue", border = NA)
plot(ascisse,F,type = ’n’, ylab = ’’, xlab = ’’)
lines(ascisse, F)
lines(ascisse, F_eta)
polygon(c(ascisse, rev(ascisse)),
+ c(F, rev(F_eta)), col = "blue", border = NA)
}
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We can observe that into the function simulation_test it is called one
function fe, that makes an other simulation for determining empirically Fe,
or it gives a Beta with appropriate parameters when we have constant rein-
forcements.
fe = function(r0, g0, m, tipo_rinforzo, passo, delta, eta) {
n_iterazioni = 10000;
k = 100;
r = rep(r0, k);
g = rep(g0, k);
ascisse = seq(from=0, to=1, by=passo);
ordinate = rep(0, length(ascisse));
if(tipo_rinforzo != ’c’) {
for(i in c(1:n_iterazioni)) {
output = one_step_vectors(r, g, m, m, tipo_rinforzo,
+ delta, eta);
r = output[[1]];
g = output[[2]];
}
z = output[[3]];
for(i in c(1: length(ascisse))) {
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ordinate[i] = (sum(z < ascisse[i])) / k;
}
} else {
for(i in c(1:length(ascisse))) {
if(ascisse[i] < delta)
ordinate[i] = 0;
if(ascisse[i] > eta)
ordinate[i] = 1;
if(ascisse[i] >= delta && ascisse[i] <= eta)
ordinate[i] = pbeta((ascisse[i] - delta)/(eta-delta),
+ r0/m, g0/m);
}
}
return(ordinate)
}
.2 Power
In this section we display the function built to find the minimun power.
potenza = function(alpha, delta0, n0, p0 = 0.5, +
+ sigmaR = 0.5, sigmaG = 0.5) {
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z = qnorm(1 - alpha/2);
ascisse = seq(from=0, to=2, length=100);
err = pnorm(-z-ascisse/(sqrt(sigmaR*sigmaR/(n0*p0) +
+ sigmaG*sigmaG/(n0*(1-p0))))) +
+ pnorm(z-ascisse/(sqrt(sigmaR*sigmaR/(n0*p0) +
+ sigmaG*sigmaG/(n0*(1-p0)))))
potenza = 1 - err
plot(ascisse, potenza, type="l", col = "Grey", +
+ xlab = "Delta", ylab = "Potenza", xlim = c(0, 1))
abline(v = delta0, col = "Red")
abline(h = 0, col = "Grey")
abline(h = 1, col = "Grey")
potenza_minima = 1 - pnorm(-z-delta0/(sqrt(sigmaR*sigmaR/(n0*p0) +
+ sigmaG*sigmaG/(n0*(1-p0))))) +
- pnorm(z-delta0/(sqrt(sigmaR*sigmaR/(n0*p0) +
+ sigmaG*sigmaG/(n0*(1-p0)))))
abline(h = potenza_minima, col = "Red")
return(potenza_minima);
}
Now we show the function regions that produces the graph of regions
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A, B, C.
regions = function(n0, p0 = 0.5, sigmaR = 0.5, sigmaG = 0.5) {
p_opt = sigmaR / (sigmaR + sigmaG);
ascisse = seq(from=0, to=1, length=100);
n = (p_opt*p_opt/ascisse + (1-p_opt)*(1-p_opt)/(1-ascisse)) +
+ / (p_opt*p_opt/(n0*p0) + (1-p_opt)*(1-p_opt)/(n0*(1-p0)));
A_limit = p0 * n0 / ascisse
C_limit = (1 - p0) * n0 / (1 - ascisse)
plot(ascisse, n, type = "l", col = "Blue", +
+ ylim = c(0, 1000), xlab = "p", ylab = "n")
par(new="T")
plot(ascisse, A_limit, type = "l", col = "Red", +
+ ylim = c(0, 1000), xlab = "", ylab = "")
par(new="T")
plot(ascisse, C_limit, type = "l", col = "Red", +
+ ylim = c(0, 1000), xlab = "", ylab = "")
}
The function delta_eta computes for a fixed n the intervals in which  
and ⌘ have to vary in order that the tests belong to the proper region.
delta_eta = function(n, n0, p0 = 0.5, +
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+ sigmaR = 0.5, sigmaG = 0.5) {
nn = function(x) {
p_opt = sigmaR / (sigmaR + sigmaG);
return((p_opt*p_opt/x + (1-p_opt)*(1-p_opt)/(1-x)) +
+ / (p_opt*p_opt/(n0*p0) + (1-p_opt)*(1-p_opt) +
+ /(n0*(1-p0)))-n);
}
delta_inf = uniroot(nn, c(0.1, p0));
delta_sup = n0 * p0 / n;
eta_inf = 1 - n0 * (1 - p0) / n;
eta_sup = uniroot(nn, c(p0, 0.9));
return(c(delta_inf, delta_sup, eta_inf, eta_sup))
}
simulation_power = function(alpha, n0, p0, n, delta, eta, +
+ K, mr, mg, sigmaR = 0.5, sigmaG = 0.5, r0 = 200, g0 = 200) {
z = qnorm(1 - alpha/2);
potenza = function(n, p) {
differenza = abs(mr - mg);
return(1 - pnorm(-z-differenza/(sqrt(sigmaR*sigmaR/(n*p) +
+ sigmaG*sigmaG/(n*(1-p))))) +
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- pnorm(z-differenza/(sqrt(sigmaR*sigmaR/(n*p) +
+ sigmaG*sigmaG/(n*(1-p))))))
}
Ra = function(p) {
return(sqrt(sigmaR*sigmaR/(n*p) +
+ sigmaG*sigmaG/(n*(1-p)))*z)
}
Nr = rep(0, K);
Ng = rep(0, K);
P = rep(0, K);
Xr = rep(0, K);
Xg = rep(0, K);
Potenza = rep(0, K);
Test = rep(0, K);
for(j in c(1: K)) {
r = r0;
g = g0;
xr = 0;
xg = 0;
nr = 0;
ng = 0;
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for(i in c(1 : n)) {
output = one_step_test(r, w, mr, mg, ’n’,
+ delta, eta, xr, xg, nr, ng);
r = output[1];
g = output[2];
xr = output[3];
xg = output[4];
nr = output[5];
ng = output[6];
}
Nr[j] = nr;
Ng[j] = ng;
P[j] = nr / n;
Xr[j] = xr / nr;
Xg[j] = xg / ng;
Potenza[j] = potenza(n, P[j]);
Test[j] = ifelse(abs(Xr[j] - Xw[j]) > Ra(P[j]), 1, 0);
}
cat("Potenza calcolata: ", mean(Potenza), "\n");
cat("Potenza empirica: ", mean(Test), "\n");
cat("Potenza migliorata: ", +
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+ sum(Potenza>potenza(n0, p0))/K, "\n");
cat("Media del numero di pazienti assegnati +
+ al primo trattamento: ", mean(Nr), "\n");
cat("Media del numero di pazienti assegnati +
+ al secondo trattamento: ", mean(Ng), "\n");
}
The function simulation_power uses the function one_step_test. This
is the R code.
one_step_test = function(r, g, mr, mg, tipo_rinforzo, +
+ delta, eta, xr, xg, nr, ng) {
z = r / (r + g);
x = rbinom(1, 1, z);
if(tipo_rinforzo == ’n’) {
m = rnorm(1, mr);
n = rnorm(1, mg);
} else if (tipo_rinforzo == ’c’) {
m = mr;
n = mg;
} else if (tipo_rinforzo == ’e’) {
m = rexp(1, mr);
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n = rexp(1, mg);
}
if(z < eta)
r = r + x*m;
if(z > delta)
w = w + (1-x)*n;
if(x == 0){
xg = xg + n;
ng = ng + 1;
}
else{
xr = xr + m;
nr = nr + 1;
}
return(c(r, w, xr, xg, nr, ng));
}
.3 Melased
Upload of the dataset.
dataset = read.csv("mela.csv", header=TRUE, sep=";", dec=".")
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Outcome construction: cumulative amount of sedative
poat_paz = sapply(split(dataset$poat, dataset$id), sum)
pobz_paz = sapply(split(dataset$pobz, dataset$id), sum)
poal_paz = sapply(split(dataset$poal, dataset$id), sum)
evpr_paz = sapply(split(dataset$evpr, dataset$id), sum)
evbz_paz = sapply(split(dataset$evbz, dataset$id), sum)
evop_paz = sapply(split(dataset$evop, dataset$id), sum)
somma_sed_paz = poat_paz + pobz_paz + poal_paz + evpr_paz + evbz_paz + evop_paz
MAX = floor(max(somma_sed_paz))
id_paz = unique(dataset$id)
index_paz = match(id_paz, dataset$id)
gruppi_paz = dataset$gruppo[index_paz]
somma_sed_inv = MAX - somma_sed_paz
Final dataset with new id (repeated mesaures)
dataset_rev = data.frame(id_paz, gruppi_paz, somma_sed_paz, somma_sed_inv)
somma_sed_0 <- dataset_rev$somma_sed_inv[(dataset_rev$gruppi_paz==0)&(is.na(dataset_rev$somma_sed_inv)==F)]
somma_sed_1 <- dataset_rev$somma_sed_inv[(dataset_rev$gruppi_paz==1)&(is.na(dataset_rev$somma_sed_inv)==F)]
n_1 <- length(somma_sed_1)
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n_0 <- length(somma_sed_0)
We made some graphical checks on the distribution of the responses.
plot(density(dataset_rev$somma_sed_paz[dataset_rev$gruppi_paz=="0"], main="Density on Placebo subjects",xlim=c(0,18)))
plot(density(dataset_rev$somma_sed_paz[dataset_rev$gruppi_paz=="1"], main="Density on Melatonin subjects",xlim=c(0,18)))
plot(dataset_rev$somma_sed_paz[dataset_rev$gruppi_paz=="0"], main="Density on Placebo subjects",xlim=c(0,18))
plot(dataset_rev$somma_sed_paz[dataset_rev$gruppi_paz=="1"], main="Density on Melatonin subjects",xlim=c(0,18))
windows()
hist(somma_sed_1)
windows()
hist(somma_sed_0)
t.test(somma_sed_1,somma_sed_0)
hist(somma_sed_0, main = ’Cumulative Sedative for Placebo’)
hist(somma_sed_1, main = ’Cumulative Sedative for Melatonin’)
Descriptive analysis.
summary(dataset_rev)
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sd(dataset_rev$gruppi_paz)
To compare the results between the RRU test and the classical one, we
need to compute the test on the controlled randomized trial.
simulazione_Ttest = function(dataset, nr, ng, Npazienti, Nsimulazioni, alpha, cutoff) {
output = inizializza(dataset, cutoff);
listaPazienti0 = output$pazienti0
listaPazienti1 = output$pazienti1
pazienti1 = c()
potenza1 = 0
for(i in 1:Nsimulazioni) {
output = simulazione_bootstrap(dataset, nr, ng, Npazienti[1], listaPazienti0, listaPazienti1, alpha, cutoff)
pazienti1[i] = output$pazienti0
potenza1 = potenza1 + output$test
}
potenza1 = potenza1 / Nsimulazioni
pazienti2 = c()
potenza2 = 0
for(i in 1:Nsimulazioni) {
output = simulazione_bootstrap(dataset, nr, ng, Npazienti[2], listaPazienti0, listaPazienti1, alpha, cutoff)
pazienti2[i] = output$pazienti0
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potenza2 = potenza2 + output$test
}
potenza2 = potenza2 / Nsimulazioni
pazienti3 = c()
potenza3 = 0
for(i in 1:Nsimulazioni) {
output = simulazione_bootstrap(dataset, nr, ng, Npazienti[3], listaPazienti0,
listaPazienti1, alpha, cutoff)
pazienti3[i] = output$pazienti0
potenza3 = potenza3 + output$test
}
potenza3 = potenza3 / Nsimulazioni
boxplot(pazienti1, pazienti2, pazienti3, names=c(paste(Npazienti[1],
"pazienti\nPotenza", 1-potenza1), paste(Npazienti[2], "pazienti\nPotenza", 1-potenza2), paste(Npazienti[3],
"pazienti\nPotenza", 1-potenza3)), col=c("cornflowerblue", "cornflowerblue", "cornflowerblue"))
abline(h=41,col=’red’)
}
Classical test with the bootstrap method.
test_rct <- rep(0,ripetizioni)
R CODE 119
for (j in 1:ripetizioni) {
M <- u_inv(F_1(n_1))
N <- u_inv(F_0(n_0))
m_R <- mean(M)
m_G <- mean(N)
s_R <- sqrt( sum( (M-m_R)^2 ) / (n_1-1) )
s_G <- sqrt( sum( (N-m_G)^2 ) / (n_0-1) )
nu <- ( (s_R^2/n_1) +
(s_G^2/n_0) )^2 / ( (s_R^2/n_1)^2/(n_1-1) + (s_G^2/n_0)^2/(n_0-1) )
RC[j] <- sqrt( (s_R^2/n_1) + (s_G^2/n_0) ) * qt(alpha/2,nu,0,FALSE)
test_rct[j] <- abs(mean(M) - mean(N)) > RC[j]
}
R code for the boxplots.
pow <- sum(pow_t)/10000
par(mfrow=c(1,3))
boxplot(n_G, col=’blue’, main=’SAMPLE = 82’, ylab=’Patients assigned
to Placebo’, xlab=’power = 0.80’, ylim=c(0,150))
boxplot(n_G, col=’forestgreen’, main=’SAMPLE = 102’,ylab=’Patients assigned
R CODE 120
to Placebo’, xlab=’power = 0.85’, ylim=c(0,150))
boxplot(n_G, col=’forestgreen’, main=’SAMPLE = 122’,ylab=’Patients assigned
to Placebo’, xlab=’power = 0.89’, ylim=c(0,150))
